Skip to main content
SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD logo

SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000078 ISIN · CNE000000X95 LEI · 300300J4GCOV7CYQTB51 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,619 across all filing types
Latest filing 2021-03-05 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 000078

About SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD

https://www.neptunusbio.com

Shenzhen Neptunus Bioengineering Co., Ltd. is a comprehensive healthcare enterprise focused on the research, development, manufacturing, and distribution of pharmaceutical products. The company operates across the entire industry value chain, including the production of chemical drugs, biological preparations, and traditional Chinese medicines. Its portfolio extends to medical devices and health supplements. A significant component of its operations involves a large-scale pharmaceutical distribution network and a nationwide retail pharmacy chain. The company emphasizes innovation in biotechnology and maintains modern production facilities to support its diverse product lines. By integrating R&D with a robust logistics and retail infrastructure, it provides a wide range of healthcare solutions to medical institutions and consumers.

Recent filings

Filing Released Lang Actions
关于为控股子公司提供担保的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Shenzhen Haiwang Bioengineering Co., Ltd. regarding guarantees provided for loans and supplier payments by its controlling subsidiaries. It includes extensive financial data and business details of the subsidiaries, as well as the terms and conditions for the guarantees. The document is not a full financial report like an annual or interim report, nor is it a transcript, audit report, or management report. It is a specific announcement about financing-related guarantees and credit support activities. This fits best under the category of Capital/Financing Update (CAP), as it relates to the company's financing activities and guarantees for subsidiaries' borrowings. The document length is substantial and contains detailed financial data relevant to the guarantees, supporting a confident classification as CAP.
2021-03-05 Chinese
关于中国证券监督管理委员会深圳监管局对公司采取责令改正措施决定的整改报告
Audit Report / Information Classification · 95% confidence The document is a detailed corrective action report issued by Shenzhen Haier Bioengineering Co., Ltd. in response to a regulatory decision by the China Securities Regulatory Commission Shenzhen Bureau. It addresses multiple compliance issues including corporate governance, accounting irregularities, internal control deficiencies, and bond management. The document includes specific problem descriptions, corrective measures, responsible departments, and timelines. It is not a financial report like an annual or interim report, nor is it a simple announcement or certification. It is a comprehensive audit-related corrective report responding to regulatory findings, which fits the category of an Audit Report / Information (AR). The document length (over 14,000 characters) and detailed content confirm it is the report itself, not just an announcement. Therefore, the appropriate classification is AR with high confidence. FY 2020
2021-03-05 Chinese
关于召开2021年第一次临时股东大会通知的公告
AGM Information Classification · 95% confidence The document is a detailed announcement regarding the convening of the 2021 first extraordinary general meeting (临时股东大会) of Shenzhen Haier Bioengineering Co., Ltd. It includes information about the meeting date, voting procedures (both onsite and online), agenda items to be discussed and voted on, registration details, and proxy authorization forms. The document does not contain financial statements or results but is focused on notifying shareholders about the meeting and how to participate and vote. It is not a report of voting results, nor is it a proxy solicitation statement, but rather a formal meeting notice. Given the content and purpose, this fits the category of AGM Information (AGM-R), which covers presentations and materials shared during or related to the Annual or Extraordinary General Meeting, including meeting notices and agendas.
2021-03-05 Chinese
关于为参股公司提供同比例担保的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the company providing proportional guarantees for loans taken by an associate company. It includes details about the guarantee amount, the associate company, board approval, independent directors' opinions, and cumulative guarantee exposure. The document is relatively short (2200 characters) and focuses on a specific financing-related event rather than comprehensive financial data or report. It does not contain financial statements or detailed financial analysis. The content fits the category of a Capital/Financing Update, as it relates to the company's financing activities and guarantees provided to support an associate's borrowing. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2021-03-05 Chinese
监事会关于第八届监事会第十一次会议相关事项的意见
Regulatory Filings Classification · 95% confidence The document is a formal opinion statement from the Supervisory Board of Shenzhen Haiwang Bioengineering Co., Ltd. regarding specific matters discussed in their meeting, including opinions on a rectification report related to regulatory corrective measures by the China Securities Regulatory Commission Shenzhen Bureau, and opinions on guarantees provided to subsidiaries and associated companies. The document does not contain financial statements or detailed financial data, nor is it an announcement of a shareholder vote or management change. It is a regulatory compliance-related supervisory board opinion document. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is not a certification letter or a short announcement of a report publication. The best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2021-03-05 Chinese
第八届监事会第十一次会议决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Shenzhen Haiwang Bioengineering Co., Ltd. It details the convening and decisions made during the 11th meeting of the 8th Supervisory Board, including approval of corrective action reports and guarantees for subsidiaries. The document references regulatory compliance and voting results but does not contain financial statements or detailed financial data. It is a formal announcement of board meeting resolutions rather than a full management report or financial report. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by company boards or senior management bodies.
2021-03-05 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.